← Leaderboards
Philip Lograsso
Scripps Research Institute, The
$9,674,964
Attributed
$9,971,964
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2007–14$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$17,672,510 · 5
By mechanism
U01$15,401,092 · 2
R01$1,677,418 · 2
R21$594,000 · 1
Top collaborators
- Yangbo Feng2 shared
Most similar at Scripps Research Institute, The
Same institution · by research overlap
- Theodore M Kamenecka$11,110,151
- Fai Yiu Siu$159,186
- Michael Rivera Luzung$91,672
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignCellsSmall MoleculeIn VivoSeriesProgramsPharmacologyDrug KineticsDrug MetabolismInhibitor/AntagonistPathologyPhosphorylationBaseLeadBiochemicalAdverse EffectsComplementRattusPharmaceutical ChemistryClinical TrialsPenetrationPeptidesParkinson DiseaseClinical Treatment
Grant awards (18)
Assay Development for Substrate and Phosphorylation State Specific JNK Inhibitors$359,100
R01 · FY2014 · GM · contact PI
Assay Development for Substrate and Phosphorylation State Specific JNK Inhibitors$359,100
R01 · FY2013 · GM · contact PI
Preclinial Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,594,607
U01 · FY2012 · NS · contact PI
Preclinical Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,594,607
U01 · FY2012 · NS · contact PI
Development of small molecule Limk inhibitors for probing ocular diseases$297,000
R21 · FY2012 · EY
Preclinical Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,620,133
U01 · FY2011 · NS · contact PI
Preclinial Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,620,133
U01 · FY2011 · NS · contact PI
Development of small molecule Limk inhibitors for probing ocular diseases$297,000
R21 · FY2011 · EY
Preclinical Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,378,687
U01 · FY2010 · NS · contact PI
Preclinial Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,378,687
U01 · FY2010 · NS · contact PI
Development of cAMP Biosensor, High Content Imaging, and Functional GLP-1R aSSAYS$11,323
R01 · FY2010 · DK · contact PI
Preclinical Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,603,454
U01 · FY2009 · NS · contact PI
Preclinial Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,603,454
U01 · FY2009 · NS · contact PI
Development of cAMP Biosensor, High Content Imaging, and Functional GLP-1R aSSAYS$313,830
R01 · FY2009 · DK · contact PI
Preclinial Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,503,665
U01 · FY2008 · NS · contact PI
Preclinical Development of JNK3 Inhibitors to Treat Parkinson's Disease$1,503,665
U01 · FY2008 · NS · contact PI
Development of cAMP Biosensor, High Content Imaging, and Functional GLP-1R aSSAYS$313,830
R01 · FY2008 · DK · contact PI
Development of cAMP Biosensor, High Content Imaging, and Functional GLP-1R aSSAYS$320,235
R01 · FY2007 · DK · contact PI